WallStreetZenWallStreetZen

NASDAQ: MESO
Mesoblast Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MESO

Based on 1 analyst offering 12 month price targets for Mesoblast Ltd

Min Forecast
$24.00+120.39%
Avg Forecast
$24.00+120.39%
Max Forecast
$24.00+120.39%

Should I buy or sell MESO stock?

Based on 1 analyst offering ratings for Mesoblast Ltd.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MESO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MESO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MESO stock forecasts and price targets.

MESO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-07

1 of 1

Forecast return on equity

Is MESO forecast to generate an efficient return?

Company
N/A
Industry
165.61%
Market
89.98%

Forecast return on assets

Is MESO forecast to generate an efficient return on assets?

Company
N/A
Industry
43.22%

MESO earnings per share forecast

What is MESO's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.43
Avg 2 year Forecast
$0.80

MESO revenue forecast

What is MESO's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$63.5M+1,019.49%
Avg 2 year Forecast
$286.3M+4,949.38%
MESO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MESO revenue growth forecast

How is MESO forecast to perform vs Biotechnology companies and vs the US market?

Company
347.8%
Industry
56.23%
Market
10.33%
MESO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MESO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MESO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MESO$10.89$24.00+120.39%Strong Buy
INVA$20.09$55.00+173.77%Buy
CVAC$5.43$6.83+25.84%Hold
TVTX$14.80$36.10+143.92%Strong Buy
GPCR$20.74$67.80+226.90%Strong Buy
View Top Biotech Stocks

Mesoblast Stock Forecast FAQ

Is Mesoblast Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MESO) stock is to Strong Buy MESO stock.

Out of 1 analyst, 1 (100%) are recommending MESO as a Strong Buy, 0 (0%) are recommending MESO as a Buy, 0 (0%) are recommending MESO as a Hold, 0 (0%) are recommending MESO as a Sell, and 0 (0%) are recommending MESO as a Strong Sell.

If you're new to stock investing, here's how to buy Mesoblast stock.

What is MESO's earnings growth forecast for 2026-2027?

(NASDAQ: MESO) Mesoblast's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Mesoblast's earnings in 2025 is -$103,351,000.On average, 3 Wall Street analysts forecast MESO's earnings for 2026 to be -$491,748,038, with the lowest MESO earnings forecast at -$576,222,215, and the highest MESO earnings forecast at -$449,453,327.

In 2027, MESO is forecast to generate $921,955,543 in earnings, with the lowest earnings forecast at $921,955,543 and the highest earnings forecast at $921,955,543.

What is MESO's revenue growth forecast for 2026-2027?

(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 347.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.

Mesoblast's revenue in 2025 is $5,670,000.On average, 2 Wall Street analysts forecast MESO's revenue for 2026 to be $73,151,410,131, with the lowest MESO revenue forecast at $72,200,643,477, and the highest MESO revenue forecast at $74,102,176,785.

In 2027, MESO is forecast to generate $329,944,840,023 in revenue, with the lowest revenue forecast at $329,944,840,023 and the highest revenue forecast at $329,944,840,023.

What is MESO's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: MESO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 43.22%.

What is MESO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MESO price target, the average MESO price target is $24.00, with the highest MESO stock price forecast at $24.00 and the lowest MESO stock price forecast at $24.00.

The Wall Street analyst predicted that Mesoblast's share price could reach $24.00 by Feb 7, 2026. The average Mesoblast stock price prediction forecasts a potential upside of 120.39% from the current MESO share price of $10.89.

What is MESO's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: MESO) Mesoblast's current Earnings Per Share (EPS) is -$0.93. On average, analysts forecast that MESO's EPS will be -$0.43 for 2026, with the lowest EPS forecast at -$0.50, and the highest EPS forecast at -$0.39. In 2027, MESO's EPS is forecast to hit $0.80 (min: $0.80, max: $0.80).

What is MESO's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: MESO) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.